Is it true that CMS will cut reimbursement for the 340B program in 2018?


In the 2018 proposed rule for the Hospital Outpatient Prospective Payment System (OPPS), the Centers for Medicare & Medicaid Services addressed recent trends of increasing drug prices, for which some of the cost burden falls to Medicare beneficiaries. For 2018, CMS has proposed paying separately payable, non-pass-through drugs (other than vaccines) purchased at a discount through the 340B drug pricing program at an average sales price (ASP) minus 22.5 percent rather than ASP plus 6 percent. Applicable drugs not purchased under the 340B drug program would continue to receive ASP plus 6 percent payment.


CPT® copyright 2021 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.